Guerbet's 2025 Revenue Declines 3.5%
Medical imaging specialist Guerbet reported full-year 2025 revenue of €786.4 million, a 3.5% decrease on a comparable basis. The decline was attributed to lower business in France and issues at its U.S. Raleigh manufacturing site.
Guerbet, a global specialist in contrast agents and medical imaging solutions, announced its 2025 full-year revenue reached €786.4 million. This represents a 3.5% decrease when adjusted for constant exchange rates and on a like-for-like basis.
The revenue decline, which slightly exceeded the company's forecast range, was impacted by contrasting trends throughout the year. Early in the year, business in France contracted significantly. However, the fourth quarter saw a notable decline of 5.6% at CER and like-for-like, primarily due to operational issues at the Raleigh industrial site in North Carolina, United States. Despite the revenue dip, Guerbet confirmed its forecast range for restated EBITDA for 2025, expected to be between 10.5% and 12%, and revised its free cash flow target upwards to be positive.
Geographically, the EMEA region saw a 2.5% revenue decrease (at CER and like-for-like), with France experiencing supply chain reform impacts. The Americas region reported a 3.8% decline (CER and like-for-like), partly due to delayed batch releases from the Raleigh site. Asia experienced a 4.8% decrease (CER and like-for-like), influenced by the loss of a distribution customer in Vietnam.
By business activity, Diagnostic Imaging revenue fell by 5.3% (CER and like-for-like), impacting both MRI and X-ray segments. In contrast, Interventional Imaging revenue grew by a positive 9.7% (CER and like-for-like).
Guerbet anticipates that the situation at the Raleigh site will continue to affect revenue, profitability, and cash generation in 2026.